Eosinophilic Fasciitis: New Developments and Future Directions.

Area of Science:

• Rheumatology
• Autoimmune Diseases
• Connective Tissue Disorders

Background:

• Eosinophilic fasciitis (EF), or Shulman's disease, is a rare autoimmune sclerosing connective tissue disorder.
• Its pathogenesis is not fully understood but involves fibroblast activity and eosinophil-related interleukins like IL-5.
• Triggers can include exercise, trauma, infection, or medications, though it is often idiopathic.

Purpose of the Study:

• To provide clinicians with a comprehensive summary of current knowledge on the diagnosis and management of EF.
• To highlight diagnostic challenges and treatment options for eosinophilic fasciitis.
• To review the latest advancements in understanding and treating this rare condition.

Main Methods:

• Review of current literature on eosinophilic fasciitis.
• Analysis of diagnostic workup, including blood tests, biopsy, MRI, and ultrasound.
• Evaluation of treatment strategies, including traditional and biologic therapies.

Main Results:

• EF is often misdiagnosed as other sclerosing diseases.
• Corticosteroids and methotrexate are common treatments, but many patients are refractory.
• Biologic therapies show promise in treatment-resistant cases, leading to partial disease resolution.

Conclusions:

• Accurate diagnosis of EF requires a thorough workup, with biopsy as the gold standard.
• Many EF patients do not respond to conventional treatments, necessitating alternative therapies.
• Further research is crucial for understanding EF pathogenesis, early diagnosis, and evaluating novel treatments.